NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

$1.06
-0.01 (-0.93%)
(As of 09:32 AM ET)
Today's Range
$1.06
$1.07
50-Day Range
$1.06
$1.38
52-Week Range
$1.04
$2.74
Volume
1,725 shs
Average Volume
96,663 shs
Market Capitalization
$54.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ENZ stock logo

About Enzo Biochem Stock (NYSE:ENZ)

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

ENZ Stock Price History

ENZ Stock News Headlines

The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Enzo Biochem: Fiscal Q2 Earnings Snapshot
Enzo Biochem, Inc.
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Jim Simons Trims Stake in Enzo Biochem Inc
Enzo Biochem Appoints New CEO and CFO
Enzo Biochem Inc (EZB.SG)
Enzo Biochem Inc ENZ
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/15/2019
Today
4/26/2024
Next Earnings (Estimated)
6/12/2024
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Employees
179
Year Founded
1976

Profitability

Net Income
$20.29 million
Pretax Margin
-71.07%

Debt

Sales & Book Value

Annual Sales
$31.06 million
Book Value
$1.58 per share

Miscellaneous

Free Float
43,286,000
Market Cap
$55.33 million
Optionable
Optionable
Beta
0.75

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

ENZ Stock Analysis - Frequently Asked Questions

How have ENZ shares performed in 2024?

Enzo Biochem's stock was trading at $1.39 on January 1st, 2024. Since then, ENZ shares have decreased by 22.3% and is now trading at $1.08.
View the best growth stocks for 2024 here
.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our ENZ earnings forecast
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings data on Tuesday, October, 15th. The medical research company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. The medical research company had revenue of $20.92 million for the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 36.71% and a net margin of 99.28%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.04%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Hamid Erfanian, James G Wolf and Kara Cannon.
View institutional ownership trends
.

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENZ) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners